Double-blind study comparing the in vivo efficacy of two hyaluronic acid products (high and very high molecular weight) in improving skin elasticity in cosmetic treatments. Are all hyaluronic acids the same? Points to bear in mind
Keywords:
stabilised hyaluronic acid, prevention, anti-ageing, elasticity, cross-linked hyaluronic acid, very high molecular weight hyaluronic acidAbstract
Background: Hyaluronic acid (HA) is in high demand in aesthetic medicine, leading to a wide variety of products differing in concentration, molecular weight, additives, and delivery methods. Patients often choose HA treatments based solely on the presence of HA, without understanding product-specific indications or effects. However, the formulation and application method significantly influence clinical outcomes.
Objective: To compare the effectiveness of two injectable HA products—Restylane® Vital and TKN HA3®—commonly perceived as similar despite differences in their composition and manufacturing.
Methods: A split-face study was conducted on 20 subjects. Restylane® Vital was injected on one side of the face, and TKN HA3® on the other. Objective skin elasticity was measured using the Cutometer® MPA 580. Subjective assessments included the Global Aesthetic Improvement Scale (GAIS), completed by both an independent investigator (GAIS-I) and the participants (GAIS-S), along with patient satisfaction questionnaires.
Results: Objective measurements showed differences in skin elasticity between the two products, further supported by GAIS-I evaluations. Despite these findings, subjective assessments (GAIS-S and satisfaction questionnaires) indicated that participants perceived both treatments as equally effective, with no clear preference.
Conclusions: Although both HA products produce similar visual outcomes and are often used interchangeably, their differing formulations result in distinct clinical effects. This study found that although patients perceived similar results from both products, objective assessments showed that VHMWHA was more effective than modified HA in enhancing skin elasticity.
References
1. Cisneros JL, Singla R, Del Río R. Implantes cutáneos biocompatibles en dermocosmética. Fluidos por infiltración. Piel. 1997; 12:492-496.
2. Witting M, Boreham A, Brodwolf R, et al. Interactions of hyaluronic acid with the skin and implications for the dermal delivery of biomacromolecules. Mol Pharm. 2015; 12(5):1391–1401.
3. Meyer K, Palmer JW. The polysaccharide of the vitrous humor. J Biol Chem. 1934; 107(3):629–634.
4. Kendall FE, Heidelberger M, Dawson MH. A serologically inactive polysaccharide elaborated by mucoid strains of group a hemolytic streptococcus. J Biol Chem. 1937; 118(1):61–69.
5. Boas NF. Isolation of hyaluronic acid from the cock’s comb. J Biol Chem. 1949; 181(2):573–575.
6. Balazs EA. Ultrapure hyaluronic acid and the use thereof. U.S. Patent US 4 141 973 B1. Filed 25 Oct 1977; issued 27 Feb 1979. Available from: patents.google.com (US4141973A)
7. Boeriu CG, Springer J, Kooy FK, van den Broek LAM, Eggink G. Production methods for hyaluronan. Int J Carbohydr Chem. 2013; 2013:14.
8. El Kechai N, Mamelle E, Nguyen Y, et al. Hyaluronic acid liposomal gel sustains delivery of a corticoid to the inner ear. J Control Release. 2016; 226:248-257.
9. Fallacara A, Vertuani S, Panozzo G, Pecorelli A, Valacchi G, Manfredini S. Novel Artificial Tears Containing Cross-Linked Hyaluronic Acid: An In Vitro Re-Epithelialization Study. Molecules. 2017; 22(12):2104.
10. Gao F, Yang CX, Mo W, Liu YW, He YQ. Hyaluronan oligosaccharides are potential stimulators to angiogenesis via RHAMM mediated signal pathway in wound healing. Clin Investig Med. 2008; 31(3):E106–E116.
11. De Oliveira JD, Carvalho LS, Gomes AM, Queiroz LR, Magalhães BS, Parachin NS. Genetic basis for hyper production of hyaluronic acid in natural and engineered microorganisms. Microb Cell Fact. 2016; 15(1):119.
12. Rangaswamy V, Jain D. An efficient process for production and purification of hyaluronic acid from Streptococcus equi subsp. zooepidemicus. Biotechnol Lett. 2008; 30(3):493-496.
13. Kim JH, Yoo SJ, Oh DK, et al. Selection of a Streptococcus equi mutant and optimization of culture conditions for the production of high molecular weight hyaluronic acid. Enzyme Microb Technol. 1996; 19(6):440-445.
14. Kuo JW. Practical Aspects of Hyaluronan Based Medical Products. Boston: Taylor and Francis. 2005; 1-209.
15. Knopf-Marques H, Pravda M, Wolfova L, et al. Hyaluronic Acid and Its Derivatives in Coating and Delivery Systems: Applications in Tissue Engineering, Regenerative Medicine and Immunomodulation. Adv Healthc Mater. 2016; 5(22):2841–2855.
16. De Oliveira JD, Carvalho LS, Gomes AM, Queiroz LR, Magalhães BS, Parachin NS. Genetic basis for hyper production of hyaluronic acid in natural and engineered microorganisms. Microb Cell Fact. 2016; 15(1):119.
17. Council of Europe; European Directorate for the Quality of Medicines & HealthCare. European Pharmacopoeia. General monograph Parenteral preparations (0520)—bacterial endotoxins. In: European Pharmacopoeia. Strasbourg: Council of Europe; current edition [cited 2025 Sep 9]. Available from: European Directorate for the Quality of Medicines & HealthCare website: revision of the Ph. Eur. dosage form monograph on Parenteral preparations (0520) adopted.
18. Kobayashi Y, Okamoto A, Nishinari K. Viscoelasticity of hyaluronic acid with different molecular weights. Biorheology. 1994; 31(3):235-244.
19. Balazs EA. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet AJ, editor. Disorders of the Knee JB. Lippincott Company; Philadelphia, PA, USA: 1974. pp. 63-75.
20. Heldin P, Lin CY, Kolliopoulos K, Chen YH, Skandalis SS. Regulation of hyaluronan biosynthesis and clinical impact of excessive hyaluronan production. Matrix Biol. 2019; 78-79:100-117.
21. Cyphert JM, Trempus CS, Garantziotis S. Size matters: Molecular weight specificity of hyaluronan effects in cell biology. Int J Cell Biol. 2015; 2015:563818.
22. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004; 4(7):528–539.
23. Fundarò SP, Salti G, Malgapo DMH, Innocenti S. The Rheology and Physicochemical Characteristics of Hyaluronic Acid Fillers: Their Clinical Implications. Int J Mol Sci. 2022; 23(18):10518.
24. Schiraldi C, La Gatta A, De Rosa M. Biotechnological Production and Application of Hyaluronan. In: Elnashar M., editor. Biopolymers. IntechOpen; London, UK: 2010.
25. Nobile V, Buonocore D, Michelotti A, Marzatico F. Anti-aging and filling efficacy of six types hyaluronic acid-based dermo-cosmetic treatment: Double blind, randomized clinical trial of efficacy and safety. J Cosmet Dermatol. 2014; 13(4):277-287.
26. Janiš R, Pata V, Egner P, Pavlačková J, Zapletalová A, Kejlová K. Comparison of metrological techniques for evaluation of the impact of a cosmetic product containing hyaluronic acid on the properties of skin surface. Biointerphases. 2017; 12(2):021006.
27. Gelardi M, Guglielmi AV, De Candia N, Maffezzoni E, Berardi P, Quaranta N. Effect of sodium hyaluronate on mucociliary clearance after functional endoscopic sinus surgery. Eur Ann Allergy Clin Immunol. 2013; 45(3):103–108.
28. Dobrev H. Cutometer®. In: Berardesca E, Maibach H, Wilhelm KP. Noninvasive diagnostic techniques in clinical dermatology. Berlin: Springer; 2014. pp. 315-338.
29. Holt B, Tripathi A, Morgan J. Viscoelastic response of human skin to low magnitude physiologically relevant shear. J Biomech. 2008; 41(12):2689-2695.
30. Lorente EL, Pérez ML. High molecular weight hyaluronic acid (HMWHA) for the treatment and prevention of skin aging. TKN HA3®® for the skin aging. Aesthetic medicine. 2022; 8(4):12-30.
31. Toskani, S.L. TKN HA 3 (Sodium hyaluronate 9 mg/ml) sterile, pyrogen-free injectable gel. IFU 01975, Rev. 03; Jun 2020 [Internet]. Available from: Mesosynergy. PDF “TKN HA3 IFU01975 Rev. 03.” https://mesosynergy.com/wp-content/uploads/2020/11/TKN-HA3-IFU01975-Rev.03.pd
32. Anido J, Félix S, Jarne C, et al. Reunión de consenso para recomendaciones sobre la gama de productos Restylane Skinboosters®. Cirugia plástica Ibero-latinoamericana. 2016; 42(2):187-195.
33. Galderma S.A. Restylane® Skinboosters™ Vital (stabilized hyaluronic acid gel). Instructions for Use, March 2020 [Internet]. Available from: Galderma website: IFU Restylane Skinboosters Vital March 2020 PDF(https://www.galderma.com/au/sites/default/files/inlinefiles/IFU%20Restylane%20Skinboosters%20Vital%20March%202020.pdf
34. Restylane Skinboosters Vital lidocaína. Centrale Fillers [Internet]. Available from: https://www.centralefillers.com/es/products/restylane-vital-lidocaine
35. Sparavigna A, Tenconi B. Efficacy and tolerance of an injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid: a monocentric 16 weeks open-label evaluation. Clin Cosmet Investig Dermatol. 2016; 9:297-305.
36. Williams S, Tamburic S, Stensvik H, Weber M. Changes in skin physiology and clinical appearance after microdroplet placement of hyaluronic acid in aging hands. J Cosmet Dermatol. 2009; 8(3):216-225.
37. Kerscher M, Bayrhammer J, Reuther T. Rejuvenating influence of a stabilized hyaluronic acid-based gel of non-animal origin on facial skin aging. Dermatol Surg. 2008; 34(5):720-726.
38. Reuther T, Bayrhammer J, Kerscher M. Effects of a three-session skin rejuvenation treatment using stabilized hyaluronic acid-based gel of non-animal origin on skin elasticity: a pilot study. Arch Dermatol Res. 2010; 302(1):37-45.
39. Gubanova EI, Dyachenko YY, Rodina MY, Koliyeva MK. New hydrobalance technology based on stabilized hyaluronic acid for long-term skin hydration. Vestn Dermatol Venerol. 2010; 86(1):94-98.
40. Distante F, Pagani V, Bonfigli A. Stabilized hyaluronic acid of non-animal origin for rejuvenating the skin of the upper arm. Dermatol Surg. 2009; 35 Suppl 1: 389-393.
41. Gubanova EI, Starovatova PA, Rodina MY. 12-month effects of stabilized hyaluronic acid gel compared with saline for rejuvenation of aging hands. J Drugs Dermatol. 2015; 14(3):288-298.
42. Ribé A, Ribé N. Neck skin rejuvenation: histological and clinical changes after combined therapy with a fractional non-ablative laser and stabilized hyaluronic acid-based gel of non-animal origin. J Cosmet Laser Ther. 2011; 13(4):154-161.
43. La Gatta A, Schiraldi C, Papa A, De Rosa M. Comparative analysis of commercial dermal fillers based on crosslinked hyaluronan: Physical characterization and in vitro enzymatic degradation. Polym Degrad Stab. 2011; 96(4):630-636.
44. Lee W, Hwang SG, Oh W, Kim CY, Lee JL, Yang EJ. Practical Guidelines for Hyaluronic Acid Soft-Tissue Filler Use in Facial Rejuvenation. Dermatol Surg. 2020; 46(1):41-49.
45. Stern R, Kogan G, Jedrzejas MJ, Šoltés L. The many ways to cleave hyaluronan. Biotechnol Adv. 2007; 25(6):537-557.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mayka González Martín, Luis Antônio de Assis, Maria de los Lanos Perez Gonzalez, Sandra Expósito González, Maria Begoña García Diaz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
